Psychedelic-assisted therapy training, and what a certificate actually gets you.

Every classic psychedelic a California therapist is likely to encounter remains a Schedule I controlled substance under federal law. Schedule I means the DEA has determined the substance has no currently accepted medical use in treatment in the United States and cannot lawfully be prescribed. As of the current edition of 21 CFR 1308.11(d) — the 'hallucinogenic substances' paragraph of Schedule I — psilocybin, psilocyn, LSD, ibogaine and mescaline are all listed, and MDMA is listed at 21 CFR 1308.11(d)(11). Nothing has been rescheduled.

Ketamine is the exception, and it is the reason ketamine-assisted psychotherapy exists as a legal practice at all. Ketamine sits in Schedule III at 21 CFR 1308.13(c)(7), is FDA-approved (as Ketalar) as an injectable general anaesthetic, and can therefore be prescribed by a licensed prescriber — including off-label for psychiatric indications. See the ketamine section.

There has been no DEA rulemaking to reschedule psilocybin or MDMA. A search of the Federal Register for DEA rules and proposed rules mentioning psilocybin published since 1 January 2024 returns zero results. DEA scheduling activity in this space during 2025-26 has run the other way: new analogues have been added to Schedule I, including the temporary placement of 2-fluorodeschloroketamine (a ketamine analogue, not ketamine) in Schedule I effective May 2026.

What did change, dramatically, is federal policy posture. On 18 April 2026 President Trump signed Executive Order 14401, 'Accelerating Medical Treatments for Serious Mental Illness' (91 FR 21709). It directs the FDA Commissioner to issue National Priority Vouchers to psychedelic drugs holding Breakthrough Therapy designation; directs FDA and DEA to build a Right to Try pathway for psychedelics including ibogaine, with Schedule I handling authorizations for treating physicians; allocates at least $50 million through ARPA-H to partner with states developing psychedelic programs; and — in Section 5 — directs the Attorney General to complete rescheduling review of any Schedule I product that has successfully completed Phase 3 trials for a serious mental health disorder so rescheduling can follow approval as fast as practicable.

Read Section 5 carefully, because it is the mechanism that matters for practitioners: rescheduling is tied to FDA approval of a specific product. If psilocybin is approved as a drug, it is that approved product that gets rescheduled — not psilocybin generally, and not mushrooms. Underground and ceremonial use stays a federal crime.

On 14 July 2026 the federal government published three documents on the same day: FDA's final guidance 'Psychedelic Drugs: Considerations for Clinical Investigations' (finalising the June 2023 draft); an FDA notice of a public hearing on the future therapeutic use of psychedelic drugs, set for 14 September 2026; and — most relevant to anyone weighing a training program — an HRSA Request for Information on 'Training and Care Delivery Models for Safe Administration of Potential FDA-Approved Psychedelic Therapies in Ambulatory Clinical Settings'. The RFI comment period closes 13 August 2026.

The HRSA RFI is worth reading in full before spending money on training, because it shows the federal government has not decided who gets to do this work. It explicitly asks whether providers should be required to hold a professional degree (social work, psychologist, other), whether they should need a medical degree, whether peers or trained non-professionals could serve, whether a state licensing requirement is needed, and what training model works best (didactic, simulation, supervised practicum, apprenticeship, certification). No credential is settled. Anyone selling you certainty about what credential will be required is guessing.

In June 2024 an FDA advisory committee voted against Lykos Therapeutics' new drug application for MDMA-assisted therapy for PTSD — 9 to 2 against on effectiveness — and in August 2024 the FDA issued a Complete Response Letter rejecting the application and requiring an additional Phase 3 trial. That is the last major regulatory event for MDMA-AT, and as of August 2026 it has not been reversed.

The company itself no longer exists under the Lykos name. Every trial in the MAPS/Lykos MDMA program now appears on ClinicalTrials.gov under the sponsor 'Resilient Pharmaceuticals' — including the two pivotal Phase 3 trials, MAPP1 (NCT03537014) and MAPP2 (NCT04077437), whose sponsor records were updated to that name in June 2025. Independent reporting in Salon (25 June 2026) describes Resilient Pharmaceuticals as 'the for-profit company that was spun off as the corporate arm of MAPS with the intention of selling legal MDMA once the drug is FDA-approved'. The lykostx.com domain now resolves to a parked-domain lander with no content.

Critically, there is no registered confirmatory Phase 3 trial. A search of ClinicalTrials.gov for studies led by Resilient Pharmaceuticals returns 30 records; the only recent forward-moving study is NCT07584720, 'Study of Midomafetamine in Healthy Adults' — a Phase 1 study, active but not recruiting, last updated 29 June 2026. Midomafetamine is the international nonproprietary name for MDMA. A Phase 1 healthy-volunteer study is not the additional Phase 3 the FDA asked for. On the public record, MDMA-assisted therapy is years away from a resubmission, not months.

The clearest signal of where the FDA's PTSD interest has moved came on 24 April 2026, when the agency — acting six days after Executive Order 14401 — announced national priority vouchers for three psychedelic programs. The FDA's own press release lists them by indication: psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD. Not MDMA. Secondary reporting identifies the three recipients as Compass Pathways, the Usona Institute and Transcend Therapeutics; Transcend's TSND-201 (methylone) is an MDMA-adjacent compound developed in part to avoid the trial-design and blinding problems that sank the Lykos application.

The honest summary for a therapist: MDMA-assisted therapy was the program that made 'psychedelic-assisted therapy' a phrase clinicians recognized, and it is the one program that has gone backwards. If you are choosing a training on the assumption that MDMA-AT will be approved soon and you will need the credential, that assumption is not supported by the current record.

Compass Pathways (Nasdaq: CMPS) is the furthest along of any psychedelic drug developer. In its second-quarter 2026 results, filed with the SEC on 5 August 2026, the company reported two highly statistically significant positive Phase 3 trials of COMP360 synthetic psilocybin in treatment-resistant depression — COMP005 and COMP006 — with more than 1,000 participants in the late-stage program.

The regulatory picture as of 5 August 2026: the FDA granted Compass a rolling NDA submission and review request in April 2026 on the strength of the Phase 3 data; some modules have been submitted and the company expects to complete the filing in Q4 2026. It holds a National Priority Voucher, which it says has the potential to compress review to one to two months. Compass expects commercial launch in the first half of 2027, subject to FDA approval and to DEA rescheduling afterwards. It reported $433.3 million in cash at 30 June 2026, funding into 2028.

The Usona Institute, a Wisconsin non-profit, is running the second psilocybin program. Its Phase 3 study, NCT06308653 ('A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder'), enrolled 238 participants, began March 2024, reached actual primary completion on 5 January 2026, and is listed as active and not recruiting with estimated study completion 30 January 2027. Usona also holds a national priority voucher. Its indication — major depressive disorder rather than treatment-resistant depression — would cover a much larger population if approved.

There is one finding in the Compass filing that every therapist considering a psilocybin training should sit with. Compass reports a peer-reviewed post-hoc analysis in the Journal of Psychopharmacology showing that the 'monitoring and support' provided during COMP360 administration sessions was minimal and non-directive, with almost 80% of the administration session spent in silence — and the company frames this as evidence that clinical outcomes are attributable to the drug experience rather than to psychotherapy. Compass presents this as a feature, not a limitation: it argues COMP360 will 'fit seamlessly' into existing infrastructure of more than 8,000 centers already offering multi-hour treatments, with post-approval focus on site preparedness, REMS certification and reimbursement.

In other words, the commercial model that is closest to approval is deliberately being positioned as a drug-plus-monitoring model, not a therapy model. That has direct consequences for how many billable therapist hours the approved pathway will actually contain, and it is a live scientific and political argument, not a settled question — which is precisely why the FDA scheduled a public hearing for September 2026 and HRSA opened an RFI on who should deliver this care.

This is the section that matters most, and the answer is blunt. In California in 2026 there is no legal, regulated psychedelic therapy of any kind. There is no facilitator license, no service center license, no state-authorized therapeutic use, and no bill pending that would create one. Psilocybin, LSD, ibogaine, mescaline and peyote are all Schedule I under California Health and Safety Code section 11054(d) as well as federally.

SB 519 (Wiener, 2021-22) would have decriminalised possession of several psychedelics. It was gutted in the Assembly: by the time it reached the floor its title had been amended to 'Controlled substances: study of decriminalization of certain hallucinogenic substances'. It was ordered to the inactive file on 25 August 2022, died on the inactive file on 30 November 2022, and never became law.

SB 58 (Wiener, 2023) got further than any psychedelic bill in California history. It passed both houses — the Assembly 42 ayes to 11 noes on 6 September 2023, with Senate concurrence 21 to 14 the next day — and was enrolled and presented to the Governor on 13 September 2023. Governor Newsom vetoed it on 7 October 2023. The Senate's consideration of the veto was pending until 25 January 2024, when the veto was sustained and the bill stricken from file.

The veto message is the single most important California document for anyone in this field, because Newsom did not reject psychedelic therapy — he rejected the sequencing. He wrote: 'Both peer-reviewed science and powerful personal anecdotes lead me to support new opportunities to address mental health through psychedelic medicines like those addressed in this bill... This is an exciting frontier and California will be on the front-end of leading it.' He then set a condition: 'California should immediately begin work to set up regulated treatment guidelines — replete with dosing information, therapeutic guidelines, rules to prevent against exploitation during guided treatments, and medical clearance of no underlying psychoses. Unfortunately, this bill would decriminalize possession prior to these guidelines going into place, and I cannot sign it.' He closed by urging the legislature to 'send me legislation next year that includes therapeutic guidelines.'

The legislature tried. SB 1012 (Wiener and Ashby, 2024), the Regulated Psychedelic Facilitators Act, was the direct response to that veto message — a facilitator-licensing and regulated-access framework. It cleared two policy committees (Business, Professions & Economic Development 7-4 on 15 April 2024; Public Safety 3-2 on 23 April 2024), was placed on the Senate Appropriations suspense file on 13 May 2024, was held in committee under submission on 16 May 2024, and died in committee on 30 November 2024 without ever reaching a floor vote in its house of origin. That is the closest California has come to a facilitator license, and it did not survive its first fiscal committee.

In the 2025-2026 session, a keyword search of the California Legislative Information system returns only three bills touching psilocybin or psychedelics, and none of them creates a license or authorizes therapeutic use. AB 1103 (Ward) — 'Controlled substances: research' — was approved by the Governor and filed with the Secretary of State on 10 October 2025; it reforms the Research Advisory Panel and controlled-substance research authorization process. AB 2489 (Lowenthal) — also 'Controlled substances: research' — is active in the Assembly, last amended 9 April 2026. SB 1224 (Jones), 'The California Emerging Therapies Research Partnership Act', is active in the Assembly (Veterans Affairs committee action 30 June 2026); it would create a research fund and require California to apply for ARPA-H partnership designation under the federal executive order — and it expressly prohibits the use of fund moneys for purchasing, distributing or administering a controlled substance. SB 751 (Veterans and Former First Responders Research Pilot Program) died in Senate Appropriations.

So California's actual 2025-26 policy is research infrastructure, not access. Every enacted or pending measure is about who may study these drugs, not who may administer them.

The local decriminalisation resolutions are the most misunderstood part of the California picture, and getting this wrong is how people get hurt. Oakland's is the model. Resolution No. 87731 C.M.S., introduced by Councilmember Noel Gallo and passed 7-0 on 4 June 2019, resolves that no city department, agency, board, commission, officer or employee — 'including without limitation, Oakland Police Department personnel' — shall use city funds or resources to assist in enforcing criminal penalties for adult use and possession of entheogenic plants; declares that investigation and arrest shall be 'among the lowest law enforcement priority for the City of Oakland'; directs the city's lobbyists to support decriminalisation; and calls upon the Alameda County District Attorney to cease prosecution. Santa Cruz, Arcata, San Francisco and Berkeley subsequently passed resolutions of the same character.

Two details in the Oakland text are worth noticing because they are typical of these resolutions. First, every operative clause is a statement of city policy or a request — it directs city employees, lobbies the state, and asks a county prosecutor. It changes no law. Second, the subject matter is 'entheogenic plants', defined in the resolution's own footnote as plants and natural sources such as mushrooms, cacti, iboga-containing plants and ayahuasca. Synthetic substances are not covered even by the resolution's own terms, so LSD and MDMA fall outside it entirely.

A city council cannot repeal state or federal drug law. These resolutions do not legalise anything. They do not create a defense to prosecution — a state charge can still be filed by the district attorney, and a federal charge by the US Attorney. They do not authorize sale, and they do not authorize clinical or therapeutic use by anyone. Nothing in any of them touches your license: the Board of Behavioral Sciences is a state agency and is entirely unaffected by an Oakland or Berkeley resolution. Practicing psychedelic therapy in Oakland is exactly as unlawful, and exactly as risky to your license, as practicing it in Fresno.

Ketamine-assisted psychotherapy is legal in California for one reason: ketamine is not Schedule I. It is a Schedule III controlled substance at 21 CFR 1308.13(c)(7) and is FDA-approved — as Ketalar — as an intravenous or intramuscular solution for induction and maintenance of general anaesthesia. Because it is an approved drug, a licensed prescriber may prescribe it off-label for a psychiatric indication. Off-label prescribing is ordinary medical practice; it is not a loophole. But note what the FDA says plainly: 'Ketamine is not FDA approved for the treatment of any psychiatric disorder.'

The separate product Spravato (esketamine) is FDA-approved as a nasal spray for treatment-resistant depression and for depressive symptoms in adults with MDD with acute suicidal ideation or behavior, in conjunction with an oral antidepressant. It carries a Risk Evaluation and Mitigation Strategy (REMS) requiring that it be dispensed and administered in a medically supervised, REMS-certified health care setting with a minimum two-hour post-administration monitoring period.

The practice structure follows from that. A physician, nurse practitioner or physician assistant — someone with prescriptive authority — screens, prescribes and takes medical responsibility for the dosing. The therapist provides psychotherapy: preparation before, presence and support during if the model calls for it, and integration afterwards. The therapist is not the prescriber, the dose decision is not the therapist's, and the medical monitoring is not the therapist's.

What can an LMFT legally do? Everything within Business and Professions Code section 4980.02, which defines the practice of marriage and family therapy as the application of psychotherapeutic and family systems theories, principles and methods, and expressly includes assessment, evaluation and prognosis; treatment planning; individual, relationship, family or group therapeutic interventions; psychotherapy; client education; clinical case management; consultation; and supervision. Screening for psychological suitability, preparation, being present and providing psychotherapeutic support during a session, and integration afterwards are all psychotherapy and all within scope.

What can an LMFT not do? Anything medical. An LMFT may not prescribe, may not order, may not obtain, may not possess, may not hold, may not hand to a client, may not administer, and may not adjust the dose of ketamine. An LMFT may not perform the medical monitoring — vital signs, airway, emergency response — that the FDA identifies as the point of having a health care provider present. Those acts are the practice of medicine and are outside the license.

Can an LMFT be present while the client is dosed? Yes — as the psychotherapist, in a setting where a qualified medical provider has prescribed and is responsible for medical oversight, with a written agreement that defines who is responsible for what. There is nothing in the MFT practice act that prohibits providing psychotherapy to a client who is under the influence of a lawfully prescribed medication. The risk is not presence; the risk is role drift into medical acts, or working in a setting where no prescriber is genuinely responsible.

Does an LMFT need a special credential to do KAP? No. There is no California license, certificate, registration or endorsement for ketamine-assisted psychotherapy, and no state body issues one. Every 'KAP certification' on the market is a private training credential. That does not make trainings worthless — competence in this work is real and hard-won, and a malpractice defense is easier when you can show relevant training and consultation — but nobody can require it of you and holding it grants you no additional legal authority.

The at-home and telehealth ketamine model is where the regulatory heat is. On 16 February 2022 the FDA published a compounding risk alert on the risks of at-home use of compounded ketamine nasal spray. On 10 October 2023 the FDA issued a broader warning about compounded ketamine products, including oral and sublingual formulations, prescribed for psychiatric disorders. Its reasoning is directly relevant to a therapist deciding whether to work with an at-home ketamine platform: compounded products are not FDA approved, have no FDA-approved indication or route of administration, and are not part of a REMS — and FDA states that because they are not subject to REMS monitoring requirements 'they may be less safe'. FDA specifically flags that obtaining these products through telemedicine platforms for at-home use may be attractive, but 'the lack of monitoring for adverse events, such as sedation and dissociation, by an onsite health care provider may put patients at risk', and that it has not established safe or effective dosing of ketamine for any psychiatric indication.

Practical translation: if you provide psychotherapy alongside an at-home ketamine platform, you are the only professional in the room, and you are a professional with no medical scope. Think hard about what happens if the client has an adverse event on your watch, and about how that looks in a board complaint.

Oregon Measure 109, passed November 2020 and codified as ORS 475A, created the first regulated psilocybin services program in the United States. Oregon Psilocybin Services (OPS), a section of the Oregon Health Authority's Public Health Division, began accepting license applications on 2 January 2023, and service centers opened to clients in summer 2023.

It is important to understand what the Oregon model is and is not. It is not medical treatment. There is no diagnosis requirement and no prescription. ORS 475A requires a non-directive approach: facilitators support clients without directing or projecting onto the experience. Facilitators must be present for all three components — preparation, administration and integration. A Johns Hopkins study published in the International Journal of Drug Policy in mid-June 2026, drawing on 2025 OHA data, found that most clients come from high-income backgrounds and from outside Oregon, that adverse reactions were rare, and that a significant proportion of clients used the services for general health and wellness, with change in perspective and 'expanded consciousness' the next two most common reasons. Researchers described it as 'supported adult use' and flagged safety concerns where clients present with serious medical issues.

The facilitator license requirements are specific and, notably, low-barrier by clinical standards. An applicant must be 21 or older, hold a high school diploma or equivalent, pass a criminal background check, complete an OPS-approved training program, and pass the OPS facilitator exam (75% to pass, unlimited retakes). ORS 475A.325(3) expressly bars OHA from requiring a university or college degree. A social equity plan is required with the application.

Non-residents can be licensed. ORS 475A.325(2)(c) required two years of Oregon residency only 'until January 1, 2025'. That requirement has expired, so a California-licensed therapist can hold an Oregon facilitator license. Note the contrast: service center ownership still carries a two-year Oregon residency requirement for direct owners under ORS 475A.

The training numbers, from the administrative rules: core training must be at least 128 hours of instruction (for program applications and renewals received on or after 1 January 2025) under OAR 333-333-3050. Practicum must be a minimum of 40 hours, comprising at least 30 hours of direct practice observing clients receiving psilocybin services and at least 10 hours of consultation, all conducted in person (OAR 333-333-3070). After 1 January 2026 all practicum must take place at a licensed practicum site — a licensed service center. Programs may grant accelerated training hours of up to 40% of required core hours based on professional credentialing, prior training or experience in established plant or fungi healing traditions (OAR 333-333-3080). Licensed facilitators must complete four hours of continuing education each license year.

Fees, from OAR 333-333-4060: a facilitator pays a $150 non-refundable application fee and $2,000 per year for the license, reduced to $1,000 for applicants who qualify on income grounds. A service center pays a $500 application fee and $10,000 per year, reduced to $5,000 for non-profits and qualifying applicants. Manufacturers and laboratories also pay $10,000 per year. Training programs pay a $500 application evaluation fee and must also be licensed by, or exempted by, Oregon's Higher Education Coordinating Commission.

For a licensed therapist, the most consequential recent change is Oregon HB 2387, passed in 2025 and codified at ORS 475A.338, effective 1 January 2026. It identifies seven Oregon boards — Licensed Professional Counselors and Therapists, Naturopathic Medicine, Psychology, the Oregon Medical Board, Nursing, Licensed Social Workers and Pharmacy — and provides that a person licensed by one of those boards who also holds an ORS 475A facilitator license may conduct preparation and integration sessions under both licenses simultaneously, and may conduct administration sessions so long as they do not provide health care or behavioral health care services during the administration session. It also bars those boards from disciplining a licensee for lawfully providing psilocybin services, or merely for discussing psilocybin services with a patient as a treatment option. California has no equivalent protection, and these protections run to Oregon boards only — they do not bind the California BBS.

Now the economics, which is where most people get hurt. OHA does not set or regulate prices; each service center and facilitator sets their own. As of 31 December 2024 — the most recent official OPS Year in Review — there were 345 licensed facilitators, 31 licensed service centers, 11 licensed manufacturers and 1 licensed laboratory, with 724 worker permits issued and 22 training programs holding OPS curriculum approval. Set 345 facilitators against 31 service centers and the arithmetic is obvious: there are roughly eleven licensed facilitators for every licensed venue at which they may legally practice.

The market has since contracted. Reporting by Willamette Week on OHA data, summarized in the Source Weekly on 19 August 2025, found that as of June 2025 roughly 26% of service centers had shut down since licensing began. The same reporting noted that license fee revenue has not covered the cost of administering the program — OHA has drawn more than $3 million from the state general fund, with no provision for that in the next biennium, raising the prospect of further fee increases. The Psilocybin Alliance, an industry advocacy group, attributes the difficulty to 'rising costs, complex regulations, and legislative barriers'.

The realistic picture: a facilitator license costs roughly $2,150 in state fees in year one, on top of training tuition that OPS explicitly does not regulate and does not publish, plus travel to Oregon for in-person practicum. In return you may work as a facilitator, only at a licensed service center, in a market where roughly a quarter of the venues have already closed and clients skew wealthy and out-of-state. Treat any income projection you are shown by a training program with real skepticism.

Colorado voters passed Proposition 122, the Natural Medicine Health Act, in November 2022. Senate Bill 23-290 built the regulatory structure. Two agencies share the work: the Department of Regulatory Agencies (DORA), through its Division of Professions and Occupations and Office of Natural Medicine Licensure, licenses the people; the Department of Revenue's Natural Medicine Division licenses the businesses — healing centers, cultivations, product manufacturers and testing facilities. The Colorado Department of Public Health and Environment certifies testing facilities.

The timeline is recent. DORA opened facilitator licensing in December 2024. DOR began accepting business license applications on 31 December 2024. The first Natural Medicine Handler license was issued 13 February 2025, the first Owner license 14 February 2025, the first business license 31 March 2025, and on 27 May 2025 DOR announced the first fully certified testing facility, completing the supply chain. The first psilocybin administration sessions at licensed healing centers took place in June 2025.

Colorado has four personal credential types: Facilitator, Clinical Facilitator, Distinguished Educator and Facilitator in Training (a training license). The Clinical Facilitator tier is the one that matters to an LMFT. Under 4 CCR 755-1 Rule 2.6, an applicant who holds secondary licensure as a medical or mental health licensee may petition the Director to accept coursework and practice from that secondary field as substantially equivalent to portions of an approved facilitator training program. The burden is on the applicant to demonstrate equivalence. Even on the accelerated route, the applicant must still complete 40 hours of supervised practicum, 40 hours of consultation, and a specific 25-hour module on Ethics and Colorado Natural Medicine covering the facilitator code of ethics, power and privilege, vulnerability in altered states, appropriate use of touch and a written touch contract, financial conflicts of interest, ethical advertising and scope of practice.

The standard route is 150 hours of didactic instruction, 40 hours of supervised practicum (at least 30 hours from in-person administration sessions, with no more than 10 hours creditable from the student's own experience as a participant), and 40 hours of consultation including 10 hours of ethical discussion. The 150-hour curriculum has prescribed hour allocations, and the ethics-and-boundaries weighting is striking: 25 hours on Ethics and Colorado rules, 10 hours on Relational Boundaries and Introduction to Physical Touch — which explicitly covers 'historical and contemporary abuse of power and boundary violations associated with natural medicine' — 5 hours on Facilitator Best Practices covering bias, transference and countertransference, and 25 hours on Physical and Mental Health and State. All applicants must be over 21, hold current Basic Life Support certification, and maintain it.

DORA publishes an approved training program list on its Natural Medicine homepage, with each program flagged for whether it offers didactic, practicum and consultation components. Notably, many of the DORA-approved programs are based outside Colorado — in Oregon, New York, Illinois and British Columbia — so the Colorado and Oregon training markets overlap substantially.

The market is small, and that is the part to weigh. DORA's application data, last updated 2 February 2026, shows 90 total Natural Medicine Facilitator applications, 47 Clinical Facilitator applications, 10 Distinguished Educator applications, 536 Facilitator Training License applications and 20 Training Program License applications — 703 applications in total across all credential types. On the business side, the DOR's annual report published 2 February 2026, with data as of 30 January 2026, records 52 healing center applications received and 34 approved and issued (25 micro healing centers and 9 standard healing centers), 17 cultivation applications with 13 issued, 10 products manufacturer applications with 7 issued, and 1 testing facility application, issued. In total, 80 natural medicine business applications yielded 55 issued licenses, an approval rate of 68%.

Thirty-four licensed healing centers in the entire state, against a training pipeline of more than 500 facilitator-in-training applications, is the number to hold in mind. As in Oregon, the number of people being trained substantially exceeds the number of venues where they can legally practice.

Start with the statute nobody mentions in a training brochure. Business and Professions Code section 4982 lists unprofessional conduct for LMFTs. Subdivision (c) contains this sentence: 'The board shall deny an application for a registration or license or revoke the license or registration of any person, other than one who is licensed as a physician and surgeon, who uses or offers to use drugs in the course of performing marriage and family therapy services.' Note the word 'shall'. This is not discretionary discipline on a sliding scale; on its face it is mandatory denial or revocation. The identical provision appears for LCSWs at BPC 4992.3 and for LPCCs at BPC 4999.90. It does not appear in the psychologists' unprofessional conduct statute at BPC 2960.

How broadly 'uses or offers to use drugs in the course of performing marriage and family therapy services' reaches has not, as far as this research could establish, been tested against a modern psychedelic fact pattern. A defensible reading is that it targets a therapist who supplies or administers a drug as part of therapy, and that it does not reach a therapist providing psychotherapy alongside a physician's lawful prescription. But it is written broadly, and a therapist who guides a client through an illegal psilocybin session is squarely inside any reading of it. Treat this as the single largest license-specific risk in California, and get your own lawyer's read before relying on anyone else's.

Second: providing therapy while a client uses an illegal substance. Federal law is the harder constraint. Under 21 U.S.C. 856(a) it is unlawful to knowingly open, lease, rent, use or maintain any place, permanently or temporarily, for the purpose of manufacturing, distributing or using a controlled substance, or to manage or control a place and knowingly make it available for that purpose. A therapist who hosts a psilocybin session in their office, with or without a fee, is engaging with the conduct that statute describes. Conspiracy and aiding-and-abetting exposure under 21 U.S.C. 846 and 841 sits alongside it.

California criminal law is narrower than most people assume, and the detail matters. Possession of psilocybin, psilocyn, LSD or ibogaine falls under Health and Safety Code section 11377(a)(2), a misdemeanor punishable by up to one year in county jail — not the felony-adjacent 11350. Separately, HSC 11365 makes it unlawful to be in a room or place where certain controlled substances are being used, but only where the defendant aids, assists or abets the use, and only for a specific subset of substances: HSC 11054 subdivisions (b), (c), (e), (f)(1) and paragraphs (d)(14), (15) and (20) — that is, mescaline, peyote and tetrahydrocannabinols. Psilocybin at (d)(18), psilocyn at (d)(19), LSD at (d)(12) and ibogaine at (d)(11) are not in the 11365 list. So mere presence at a psilocybin session is not itself a California 11365 offense — which is a genuinely useful distinction, and also a thin reed to build a practice on, because it says nothing about federal law, nothing about aiding and abetting the possession offense, and nothing about BPC 4982(c).

Third: integration work, which is generally lawful, and it is worth understanding why. Integration is talk therapy about an experience the client has already had. It involves no possession, no distribution, no supply, and no premises used for drug use. It sits inside the LMFT scope defined at BPC 4980.02, which expressly includes treating 'alcohol and substance use'. A therapist who helps a client make meaning of something that already happened is doing the same thing they would do with any other disclosed conduct. The line is temporal and practical: retrospective sense-making is therapy; planning a specific session, sourcing, dosing advice, coordinating with a supplier, or being present during use is a different activity with a different legal character. Documentation should make clear which one you did.

Fourth: referring a client to an underground practitioner. This is the practice most likely to look innocuous and be genuinely dangerous. A referral to someone you know intends to supply a Schedule I substance is a factual predicate for aiding and abetting or conspiracy, and it strips away the protections you rely on elsewhere — you cannot vet the practitioner's training, insurance, screening, or emergency protocol, and if the client is harmed you have no defensible standard of care to point to. Contrast Oregon, where ORS 475A.338(2)(a) affirmatively protects a health care provider from discipline for discussing licensed psilocybin services with a patient as a treatment option. California has no such protection, and no California analogue to discuss.

Fifth: traveling with clients to legal jurisdictions. The legality of the substance at the destination does not travel back with you, and it does not resolve the clinical problem. In Oregon the licensed facilitator must be present for preparation, administration and integration — so a California therapist who is not an Oregon licensee has no lawful role inside an Oregon administration session, and a California therapist who does hold an Oregon facilitator license must, under ORS 475A.338, refrain from providing behavioral health care services during the administration session. Beyond the licensing question sit the ordinary ones a board will ask: dual relationship, boundaries, informed consent, emergency planning, and whether your malpractice carrier covers any of it.

Sixth: published guidance. Neither the Board of Behavioral Sciences nor CAMFT appears to have issued public psychedelic-specific guidance that this research could locate. Do not read that silence as permission. It means no one has told you where the line is, and you will be judged against BPC 4982, the standard of care, and the facts.

Finally, the case the field does not like to discuss, and which any honest guide must include. In a MAPS-sponsored Phase 2 MDMA trial at the Vancouver site, participant Meaghan Buisson was subjected to boundary violations by the therapist pair treating her, Richard Yensen and Donna Dryer, including physical contact during dosing sessions and, after the trial, a sexual relationship with Yensen — who was not a licensed therapist. Video recorded during the trial sessions later became public. The episode is the field's defining cautionary case: it happened inside a regulated clinical trial, with a therapist dyad, with recording in place, and it still happened.

The most citable account is co-authored by Buisson herself: McNamee S, Devenot N, Buisson M, 'Studying Harms Is Key to Improving Psychedelic-Assisted Therapy — Participants Call for Changes to Research Landscape', JAMA Psychiatry 2023;80(5):411-412. It argues that serious adverse events arising from therapist-patient interactions have been systematically under-studied. Related peer-reviewed work worth reading before you enroll anywhere includes Devenot's 'Focused Bodywork as Facilitated Communication: Cautionary Perspectives on Touch in Psychedelic Therapy' (American Journal of Bioethics, January 2025) and the Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group Consensus Statement (American Journal of Bioethics, July 2024).

The empirical picture is not reassuring either. In a survey of 1,221 people reporting past psychedelic use, published in Psychedelic Medicine in March 2025, 8% reported that they or someone they knew had been the victim of inappropriate sexual contact by a psychedelic sitter, guide or practitioner. This is why both Oregon and Colorado wrote boundaries, touch and abuse-of-power modules into their mandatory curricula — Colorado allocates 25 hours to ethics and 10 hours to relational boundaries and touch, and requires a written touch contract. When you evaluate a training program, look at how many hours it spends on this, and be suspicious of any program that treats it as a footnote.